Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors

Summary

A first-in-human evaluation of SYN004, a monoclonal antibody that binds to the EGF receptor on cancer cells. Cetuximab, a marketed antibody, has been shown to be effective by inhibiting the growth of cancer cells thereby prolonging the life of patients who have received it. SYN004 is a closely related monoclonal antibody also binds to the EGF receptor in the same way. SYN004 might also inhibit cancer cells and prolong life but has been engineered to avoid some of the hypersensitivity reactions known to provoked by cetuximab.

Timeline

Start

2015-05

Primary completion

2018-10

Completion

2018-10

Drugs

Indications